WeiDingMD

PubMed

• 50 citations
  Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes.
  Sameer A. Parikh, Kari G. Rabe, Neil E. Kay, Timothy G. Call, Wei Ding
  Haematologica. 2014-01-01
• 68 citations
  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
  Emma I. Andersson, S. Pützer, Bhagwan Yadav, Olli Dufva, Sofia Khan
  Leukemia. 2018-03-01
• 74 citations
  The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
  Stefania Fiorcari, Wells S. Brown, Bradley W. McIntyre, Zeev Estrov, Rossana Maffei
  Plos One. 2013-12-23

Journal Articles

• Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre  
  Sameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology

Abstracts/Posters

• BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Role for TNF-_ in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...
  Wei Ding, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• The Future of Chronic Lymphocytic Leukemia (CLL) Therapy 
  60th American Society of Hematology Annual Meeting - 12/3/2018
• The Future of Chronic Lymphocytic Leukemia (CLL) Therapy 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018